Fluocinolone intravitreal implant (Iluvien) for macular edema secondary to immune recovery uveitis in patient with acute myeloid leukemia.

Autor: Cachero Rodríguez JM; Department of Ophthalmology, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Barakaldo, Spain. jmcachero.rod@gmail.com.; Instituto Oftalmológico Etxeandia, Galdakao, Spain. jmcachero.rod@gmail.com., Artaraz J; Department of Ophthalmology, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Barakaldo, Spain., Imaz N; Department of Ophthalmology, Donostia University Hospital, Donostia, Spain., Fonollosa A; Department of Ophthalmology, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Barakaldo, Spain.; Department of Retina, Instituto Oftalmológico Bilbao, Bilbao, Spain.
Jazyk: angličtina
Zdroj: Journal of ophthalmic inflammation and infection [J Ophthalmic Inflamm Infect] 2024 May 03; Vol. 14 (1), pp. 19. Date of Electronic Publication: 2024 May 03.
DOI: 10.1186/s12348-024-00397-y
Abstrakt: Purpose: To report the use of Fluocinolone intravitreal implant (Iluvien) for the treatment of persistent cystoid macular edema (CME) due to immune recovery uveitis syndrome in a patient with previous cytomegalovirus retinitis and acute myeloid leukemia.
Design: Case report.
Methods: The clinical history of a patient who received an Iluvien implant in one eye for the treatment of cystoid macular edema due to immune recovery uveitis syndrome, previously treated with peribulbar Triamcinolone and intravitreal Dexamethasone injections, was reviewed.
Results: A 48-year-old woman presented with cystoid macular edema due to immune recovery uveitis syndrome. The patient had a history of cytomegalovirus retinitis 3.5 years prior, secondary to immunosuppressive treatment for an acute myeloid leukemia. Three periocular triamcinolone injections and two dexamethasone intravitreal implants were performed, but the edema recurred, so fluocinolone intravitreal implant was used, achieving a sustained control of the condition at one year of follow-up.
Conclusion: The Fluocinolone intravitreal implant may be an effective treatment for persistent CME in patients with immune recovery uveitis syndrome.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje